Genmab announces newly-created Chief Financial Officer appointment
pharmafile | March 16, 2020 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Genmab, pharma
Genmab has announced the establishment of the new position of Chief Operating Officer at the company, and has furthermore named Anthony Mancini to the post. In this new role, he will oversee the company’s commercial strategies, including corporate development, business development and information technology functions
Previously in his career, Mancini has proven himself in sales, marketing and general management roles with “a consistent track record of growth across North America, Europe and Australia” and across disciplines including oncology, cardiovascular, immunology, haematology, metabolic disease and virology.
Most recently, this saw him helm the US Innovative Medicines Unit at Bristol-Myers Squibb, leading more than 1,100 staff.
With the appointment, Mancini also joins Chief Executive Officer Dr Jan van de Winkel, Chief Development Officer Dr Judith Klimovsky, and Chief Financial Officer Anthony Pagano on Genmab’s Executive Management Team.
“I am delighted to welcome Anthony to the Executive Management Team in the newly created role of Chief Operating Officer, and look forward to his contributions in building our growing global operations during this transformational stage for Genmab,” remarked CEO van de Winkel on Mancini’s appointment. “Anthony shares our determination to bring truly differentiated new cancer treatments to the market that will deliver on our commitment to improve patients’ lives while fostering a culture of excellence and passion for innovation. On behalf of the Board of Directors and the full Global Leadership Team, I warmly welcome Anthony to Genmab.”
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Genmab to submit FDA application for lymphoma therapy
Global biotechnology company Genmab plans to submit a supplemental Biologics License Application (sBLA) to the …
Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …
